WO2024144615A1 - Compound of 14'-acetoxycolladonin and 14'-acetoxybadrakemin for use as an anticancer agent in the treatment of brain and nervous system cancers - Google Patents
Compound of 14'-acetoxycolladonin and 14'-acetoxybadrakemin for use as an anticancer agent in the treatment of brain and nervous system cancers Download PDFInfo
- Publication number
- WO2024144615A1 WO2024144615A1 PCT/TR2023/051436 TR2023051436W WO2024144615A1 WO 2024144615 A1 WO2024144615 A1 WO 2024144615A1 TR 2023051436 W TR2023051436 W TR 2023051436W WO 2024144615 A1 WO2024144615 A1 WO 2024144615A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetoxybadrakemin
- acetoxycolladonin
- brain
- treatment
- nervous system
- Prior art date
Links
- 201000000220 brain stem cancer Diseases 0.000 title claims description 10
- 201000011682 nervous system cancer Diseases 0.000 title claims description 10
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 title description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 206010003571 Astrocytoma Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 206010060971 Astrocytoma malignant Diseases 0.000 claims description 3
- 206010006143 Brain stem glioma Diseases 0.000 claims description 3
- 206010014967 Ependymoma Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 201000007286 Pilocytic astrocytoma Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims description 3
- 201000007335 cerebellar astrocytoma Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 230000002267 hypothalamic effect Effects 0.000 claims description 3
- 201000007315 pineal gland astrocytoma Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 23
- 201000011510 cancer Diseases 0.000 abstract description 19
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000012829 chemotherapy agent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241001116498 Taxus baccata Species 0.000 description 2
- 208000030239 cerebral astrocytoma Diseases 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000030883 malignant astrocytoma Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to the field of cancer treatment, as mentioned. More specifically, it relates to the use of naturally derived chemotherapy agents for cancer treatment.
- Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. These cells can invade and damage nearby tissues and spread to other body parts through the bloodstream or lymphatic system. There are many different types of cancer, and they may develop in almost any part of the body.
- Chemotherapy is a commonly preferred treatment option for cancer and involves the use of medications to terminate cancer cells. Chemotherapy is an effective way to destroy cancer cells and shrink tumors, but it also damages healthy cells, leading to side effects such as nausea, vomiting, hair loss, and increased risk of infection. In addition, many cancer cells may become resistant to chemotherapy drugs during the treatment process, making it difficult to treat cancer effectively.
- Chemotherapy agents obtained from natural sources may have the potential to be more selective than synthetic chemotherapy drugs. These agents are derived from plants, animals, or other natural sources rather than being synthesized in a laboratory. Examples of chemotherapy agents obtained from natural sources include docetaxel, paclitaxel, vincristine, vinblastine, and semi-synthetic derivatives derived from the alkaloids isolated from Catharanthus roseus (rosette) plant or from 10-deacetylbaccatin III obtained from Taxus baccata (yew tree).
- chemotherapy agents obtained from natural sources for cancer treatment may offer several potential benefits compared to synthetic chemotherapy drugs.
- these agents may be less toxic to normal cells and may have other beneficial effects on the body. More research is needed to fully understand the potential of naturally obtained chemotherapy agents and identify the most effective ways to use them in cancer treatment.
- the object of the present invention is to provide a method for treating cancer using naturally derived chemotherapy agents.
- Another object of the present invention is to provide an agent suitable for cancer treatment.
- the inventors have developed pharmaceutical compositions comprising active ingredients of 14'-acetoxycolladonin or 14'-acetoxybadrakemin and optionally at least one pharmaceutically usable excipient for use as an anticancer agent in the treatment of brain and nervous system cancers, considering the problems in the state of the art described above.
- the present invention relates to pharmaceutical compositions comprising 14'- acetoxycolladonin or 14'-acetoxybadrakemin as the active ingredient and optionally at least one pharmaceutically acceptable excipient for use as a medicine in the treatment of brain and nervous system cancers.
- the active ingredient of 14'-acetoxybadrakemin (Formula II) of the invention is provided from plants belonging to the Apiaceae family.
- the 14'-acetoxycolladonin and 14'-acetoxybadrakemin molecules of the invention have a toxic effect as good as cisplatin on brain cancer cells, it has been unexpectedly observed that they have approximately 7.6 and 8.7 times less toxic effect on healthy cells than cisplatin, respectively. This shows that 14'-acetoxycolladonin and 14'-acetoxybadrakemin molecules are effective on brain and nervous system cancers and offer a much safer and selective chemotherapy possibility compared to cisplatin, a known chemotherapy agent.
- the brain and nervous system cancers mentioned within the scope of the invention may be astrocytoma, brainstem glioma, pilocytic astrocytoma, ependymoma, primitive neuroectodermal tumor, cerebellar astrocytoma, cerebral astrocytoma, glioblastoma, glioma, medulloblastoma, neuroblastoma, oligodendroglioma, pineal astrocytoma, pituitary adenoma, visual tract, and hypothalamic glioma.
- a preferred embodiment of the invention relates to the use of pharmaceutical compositions comprising 14'-acetoxycolladonin or 14'-acetoxybadrakemin as the active ingredient and optionally at least one pharmaceutically acceptable excipient in the treatment of astrocytoma, brainstem glioma, pilocytic astrocytoma, ependymoma, primitive neuroectodermal tumor, cerebellar astrocytoma, cerebral astrocytoma, glioblastoma, glioma, medulloblastoma, neuroblastoma, oligodendroglioma, pineal astrocytoma, pituitary adenoma, visual tract and hypothalamic glioma, as a therapeutic agent.
- the invention in another aspect, relates to pharmaceutical compositions containing 14'- acetoxycolladonin or 14'-acetoxybadrakemin as the active ingredient.
- the compositions of the invention may comprise at least one pharmaceutically acceptable excipient in addition to 14'- acetoxycolladonin or 14'-acetoxybadrakemin.
- the excipient may be selected from substances well known in the pharmaceutical technology that does not have any therapeutic activity that would be useful in preparing the formulation, adjusting its bioavailability, and/or release.
- compositions according to the invention may be prepared in different pharmaceutical forms considering the physical condition of the patients, the type of disease or similar conditions.
- treatment refers to the shortening of the treatment period, the acceleration of recovery, the disappearance of at least one symptom of the disease, the decrease of at least one symptom of the disease, the decrease in tumor size, the disappearance of the tumor, the decrease in the level of the relevant cancer marker or the disappearance of the cancer marker or the return of the cancer marker to a level within the limits considered normal.
- Embodiments of the invention may be combined, when technically appropriate.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the use of active ingredients of 14'-acetoxycycolladonin and 14'-acetoxybadrakemin obtained from natural sources as anticancer agents in cancer treatment and to pharmaceutical compositions comprising these agents.
Description
COMPOUND OF 14'-ACETOXYCOLLADONIN AND 14'-ACETOXYBADRAKEMIN FOR USE AS AN ANTICANCER AGENT IN THE TREATMENT OF BRAIN AND
NERVOUS SYSTEM CANCERS
Technical Field
The present invention relates to the use of active ingredients of 14'-acetoxycolladonin and 14'- acetoxybadrakemin obtained from natural sources as anticancer agents in the treatment of brain and nervous system cancers and to pharmaceutical compositions comprising one of these agents.
State of the Art
The present invention relates to the field of cancer treatment, as mentioned. More specifically, it relates to the use of naturally derived chemotherapy agents for cancer treatment.
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. These cells can invade and damage nearby tissues and spread to other body parts through the bloodstream or lymphatic system. There are many different types of cancer, and they may develop in almost any part of the body.
Chemotherapy is a commonly preferred treatment option for cancer and involves the use of medications to terminate cancer cells. Chemotherapy is an effective way to destroy cancer cells and shrink tumors, but it also damages healthy cells, leading to side effects such as nausea, vomiting, hair loss, and increased risk of infection. In addition, many cancer cells may become resistant to chemotherapy drugs during the treatment process, making it difficult to treat cancer effectively.
One way to improve my chemotherapy agents is to make them more selective so that they only target cancer cells and maintain normal cells as much as possible. Chemotherapy agents obtained from natural sources may have the potential to be more selective than synthetic chemotherapy drugs. These agents are derived from plants, animals, or other natural sources
rather than being synthesized in a laboratory. Examples of chemotherapy agents obtained from natural sources include docetaxel, paclitaxel, vincristine, vinblastine, and semi-synthetic derivatives derived from the alkaloids isolated from Catharanthus roseus (rosette) plant or from 10-deacetylbaccatin III obtained from Taxus baccata (yew tree).
The use of chemotherapy agents obtained from natural sources for cancer treatment may offer several potential benefits compared to synthetic chemotherapy drugs. For example, these agents may be less toxic to normal cells and may have other beneficial effects on the body. More research is needed to fully understand the potential of naturally obtained chemotherapy agents and identify the most effective ways to use them in cancer treatment.
Thus, the object of the present invention is to provide a method for treating cancer using naturally derived chemotherapy agents. Another object of the present invention is to provide an agent suitable for cancer treatment.
Brief Description of the Invention
The inventors have developed pharmaceutical compositions comprising active ingredients of 14'-acetoxycolladonin or 14'-acetoxybadrakemin and optionally at least one pharmaceutically usable excipient for use as an anticancer agent in the treatment of brain and nervous system cancers, considering the problems in the state of the art described above.
Detailed Description of the Invention
The present invention relates to pharmaceutical compositions comprising 14'- acetoxycolladonin or 14'-acetoxybadrakemin as the active ingredient and optionally at least one pharmaceutically acceptable excipient for use as a medicine in the treatment of brain and nervous system cancers.
The active ingredient of 14'-acetoxycolladonin (Formula I) of the invention is provided from plants belonging to the Apiaceae family.
Formula I
The active ingredient of 14'-acetoxybadrakemin (Formula II) of the invention is provided from plants belonging to the Apiaceae family.
Formula II The inventors have observed in their studies that 14'-acetoxycolladonin and 14'- acetoxybadrakemin molecules have a toxic effect on various cancer cells. It has been determined by the studies conducted by the inventors that the toxic effect of these compounds is extremely strong, especially in brain cancer cells, compared to prostate and lung cancer cells, and that it has a close and selective effect on the effect of cisplatin used as a chemotherapy agent in the known state of the art. In addition, the 14'-acetoxycolladonin and 14'- acetoxybadrakemin molecules of the invention surprisingly showed a selective effect against
brain cancer cells compared to prostate and lung cancer cells in the studies conducted by the inventors.
Although the 14'-acetoxycolladonin and 14'-acetoxybadrakemin molecules of the invention have a toxic effect as good as cisplatin on brain cancer cells, it has been unexpectedly observed that they have approximately 7.6 and 8.7 times less toxic effect on healthy cells than cisplatin, respectively. This shows that 14'-acetoxycolladonin and 14'-acetoxybadrakemin molecules are effective on brain and nervous system cancers and offer a much safer and selective chemotherapy possibility compared to cisplatin, a known chemotherapy agent.
The fact that the 14'-acetoxycolladonin and 14'-acetoxybadrakemin molecules are compounds with a structure different from the classes of molecules used in cancer treatment so far, that they have a selective effect on various types of cancer such as brain and nervous system cancers, that they have low toxicity on healthy cells and that they have a very high cytotoxic effect on cancer cells, for example at the micromolar dose level, distinguishes these molecules from other chemotherapy agents existing in state of the art and makes them superior.
The brain and nervous system cancers mentioned within the scope of the invention may be astrocytoma, brainstem glioma, pilocytic astrocytoma, ependymoma, primitive neuroectodermal tumor, cerebellar astrocytoma, cerebral astrocytoma, glioblastoma, glioma, medulloblastoma, neuroblastoma, oligodendroglioma, pineal astrocytoma, pituitary adenoma, visual tract, and hypothalamic glioma.
The pharmaceutical compositions comprising the active ingredients of 14'-acetoxycolladonin or 14'-acetoxybadrakemin of the invention are for use in the treatment of at least one or some or all of the brain and nervous system cancers mentioned herein.
A preferred embodiment of the invention relates to the use of pharmaceutical compositions comprising 14'-acetoxycolladonin or 14'-acetoxybadrakemin as the active ingredient and optionally at least one pharmaceutically acceptable excipient in the treatment of astrocytoma, brainstem glioma, pilocytic astrocytoma, ependymoma, primitive neuroectodermal tumor, cerebellar astrocytoma, cerebral astrocytoma, glioblastoma, glioma, medulloblastoma, neuroblastoma, oligodendroglioma, pineal astrocytoma, pituitary adenoma, visual tract and hypothalamic glioma, as a therapeutic agent.
In another aspect, the invention relates to pharmaceutical compositions containing 14'- acetoxycolladonin or 14'-acetoxybadrakemin as the active ingredient. The compositions of the invention may comprise at least one pharmaceutically acceptable excipient in addition to 14'- acetoxycolladonin or 14'-acetoxybadrakemin. The excipient may be selected from substances well known in the pharmaceutical technology that does not have any therapeutic activity that would be useful in preparing the formulation, adjusting its bioavailability, and/or release.
The pharmaceutical compositions according to the invention may be prepared in different pharmaceutical forms considering the physical condition of the patients, the type of disease or similar conditions.
The terms "treatment" or "therapeutic activity" mentioned within the scope of the invention refer to the shortening of the treatment period, the acceleration of recovery, the disappearance of at least one symptom of the disease, the decrease of at least one symptom of the disease, the decrease in tumor size, the disappearance of the tumor, the decrease in the level of the relevant cancer marker or the disappearance of the cancer marker or the return of the cancer marker to a level within the limits considered normal.
The expression "comprising" within the scope of the invention is also used to mean "including".
Embodiments of the invention may be combined, when technically appropriate.
Claims
1. Pharmaceutical compositions comprising 14'-acetoxycolladonin (Formula I) or 14'- acetoxybadrakemin (Formula II) as an active ingredient and optionally at least one pharmaceutically acceptable excipient for use as a medicine in the treatment of brain and nervous system cancers.
Formula II
2. A pharmaceutical composition, according to Claim 1, is characterized in that the brain and nervous system cancers are astrocytoma, brainstem glioma, pilocytic astrocytoma, ependymoma, primitive neuroectodermal tumor, cerebellar astrocytoma, glioblastoma, glioma, medulloblastoma, neuroblastoma, oligodendroglioma, pineal astrocytoma, pituitary adenoma, optic pathway, and hypothalamic glioma.
3. A pharmaceutical composition according to Claim 1 or 2, characterized in that it comprises 14'-acetoxycolladonin (Formula I) or 14'-acetoxybadrakemin (Formula II) and at least one pharmaceutically acceptable excipient.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2022/021284 | 2022-12-29 | ||
| TR2022021284 | 2022-12-29 | ||
| TR2022/021401 | 2022-12-29 | ||
| TR2022021401 | 2022-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024144615A1 true WO2024144615A1 (en) | 2024-07-04 |
Family
ID=91718803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2023/051436 WO2024144615A1 (en) | 2022-12-29 | 2023-11-30 | Compound of 14'-acetoxycolladonin and 14'-acetoxybadrakemin for use as an anticancer agent in the treatment of brain and nervous system cancers |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024144615A1 (en) |
-
2023
- 2023-11-30 WO PCT/TR2023/051436 patent/WO2024144615A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huizing et al. | Taxanes: a new class of antitumor agents | |
| DE69636531T2 (en) | METHOD, COMPOSITIONS AND KITS FOR INCREASING THE ORAL BIOVERABILITY OF PHARMACEUTICALS | |
| AU724842B2 (en) | Taxane composition and method | |
| TWI445531B (en) | Anti-tumoural effects of cannabinoid combinations | |
| Legha et al. | Phase I study of taxol using a 5-day intermittent schedule. | |
| AU2009215329B2 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| EP2144504A1 (en) | Method of treating brain cancer | |
| JP2019513812A (en) | Chemotherapy improvement | |
| JP2001513110A (en) | Tumor treatment methods | |
| US20110021620A1 (en) | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors | |
| KR20010013025A (en) | Method and compositions for administering taxanes orally to human patients | |
| ES2279157T3 (en) | EXTRACT WITH ANTITUMORAL AND ANTIVENOUS ACTIVITY. | |
| JPH10511347A (en) | Combination chemotherapy with suramin and vinca alkaloids or estramustine | |
| WO2024144615A1 (en) | Compound of 14'-acetoxycolladonin and 14'-acetoxybadrakemin for use as an anticancer agent in the treatment of brain and nervous system cancers | |
| CN109803648A (en) | The Thiolation electrophilic fatty acid of reversible protection is as prodrug | |
| EP0822815A1 (en) | A method of making pharmaceutically active taxanes orally bioavailable | |
| Elhissi et al. | Taxane anticancer formulations: challenges and achievements | |
| US20040122081A1 (en) | Pharmaceutical compositions and methods of using taxane derivatives | |
| CN103889222B (en) | Pharmaceutical composition containing paclitaxel milk surum acid esters | |
| He et al. | Application of Paclitaxel in Ovarian Cancer and Effect of Different Administration Methods | |
| US20050054716A1 (en) | Pharmaceutical compositions and methods of using taxane derivatives | |
| WO2005098027A1 (en) | Combination therapies with epothilones and carboplatin | |
| AU701607C (en) | A method of making pharmaceutically active taxanes orally bioavailable | |
| CN116270612A (en) | Method for increasing efficacy of in-band oxygen bridge medicament and application thereof | |
| CN117442558A (en) | Application of drug-loaded polymer vesicles in drug for treating acute lymphoblastic leukemia |